PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Clinical trial NCT04799314 · UNKNOWN

Trial details

NCT number: NCT04799314
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse Transplantation Chemotherapy

Start date: 2021-04-01
Primary completion: 2023-04-01
Enrollment: 132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.